AlphaGen
Access AlphaGen
Company Narratives

Crescent Star Insurance H1 2026: More Premium Written, Less Premium Earned

Crescent Star Insurance wrote more premium in H1 2026, but weak earned-premium conversion, high costs and investment losses drove a sharp reversal.

Aug 29, 2026

Company: Crescent Star Insurance Ltd | Ticker: CSIL | Reporting period: three and six months ended June 30, 2026 | Basis: unaudited unconsolidated and consolidated condensed interim financial statements. The six-month unconsolidated figures received a limited-scope review with a qualified conclusion; the standalone three-month figures were not separately reviewed. The issuer’s formal PSX identity is Crescent Star Insurance Limited. Official H1 2026 report

Alpha QoQ Score: Unavailable

TTM Performance Score: Unavailable

3Y Business Perf Score: 35.17

Sector Leadership Score: 4.7524

These four readings are AlphaGen model outputs, not company-reported figures. Unavailable readings have not been estimated.

Verdict

Crescent Star Insurance wrote more business in H1 2026, but the earnings engine deteriorated. Gross written premium increased 29.7% to Rs45.0 million, while net premium earned fell 31.7% to Rs34.8 million. That divergence matters: the company booked new cover, but a larger share remained unearned at June 30 and therefore did not yet become current-period revenue.

The loss was not primarily a claims shock. Net claims were only Rs1.1 million. The larger problem was scale: Rs71.6 million of management expenses and a Rs5.8 million premium-deficiency charge overwhelmed the premium base, producing a Rs46.5 million underwriting loss. A Rs32.7 million realized loss on investment disposals then turned investment income negative. Consolidated loss after tax reached Rs60.4 million, compared with a Rs16.0 million profit a year earlier.

Q2 itself was less weak than Q1. Company-level loss after tax narrowed to Rs11.8 million from the derived Rs39.1 million Q1 loss, and Q2 investment income returned to positive territory. That is an improvement, but not yet evidence that core underwriting is viable. The next result must show that premium is being earned faster, expense intensity is falling and the new guarantee and motor initiatives can grow without weakening risk selection.

Results at a glance

  • H1 gross written premium rose 29.7% to Rs45.0 million from Rs34.7 million.
  • H1 net premium earned fell 31.7% to Rs34.8 million from Rs51.0 million as the unearned-premium reserve increased.
  • Management expenses rose 24.7% to Rs71.6 million; they were more than twice net premium earned.
  • The underwriting loss widened to Rs46.5 million from Rs10.0 million.
  • Investment income swung to an Rs11.1 million loss from Rs13.2 million income, mainly because realized losses on disposals exceeded dividend income.
  • Unconsolidated loss after tax was Rs50.9 million versus Rs17.5 million profit; loss per share was Rs0.34 versus earnings per share of Rs0.16.
  • Consolidated loss after tax was Rs60.4 million versus Rs16.0 million profit; loss per share was Rs0.41 versus earnings per share of Rs0.15.
  • Operating cash outflow was Rs85.1 million, compared with Rs31.6 million outflow a year earlier. Net rights proceeds of Rs122.8 million prevented cash from falling further.
  • Total comprehensive loss was Rs107.9 million after a Rs56.9 million unrealized investment loss, but the rights issue lifted reported unconsolidated equity to Rs1.353 billion.

What improved

  • New business writing recovered. Q2 gross written premium increased 63.6% year on year to Rs28.4 million, and the company says it restarted guarantee business after an Islamabad High Court decision voided earlier regulatory directions.
  • Q2 investment income was Rs15.4 million, almost level with the comparable quarter. Because H1 investment income was negative Rs11.1 million, the public figures imply that the realized-loss shock was concentrated in Q1.
  • Cash premium receipts rose to Rs50.5 million from Rs39.3 million, consistent with the increase in written premium.
  • Paid-up capital increased 38% to Rs1.486 billion after the rights issue. Net proceeds of Rs122.8 million gave the company a buffer against operating and market losses.

What weakened / needs attention

  • Earned premium moved in the opposite direction from written premium. The H1 unearned-premium reserve rose to Rs23.7 million from Rs13.5 million at December 2025, delaying revenue recognition.
  • Expense intensity became unsustainable at the reported scale. Management expenses were 206% of net premium, up from 113% in H1 2025.
  • The premium-deficiency line shifted to a Rs5.8 million expense from a Rs2.0 million reversal. This indicates that expected future claims and expenses on parts of the portfolio exceeded remaining unearned premium.
  • Investment disposals produced a Rs32.7 million loss, outweighing Rs21.5 million of dividend income. Other income also fell 48.0% to Rs11.4 million.
  • Operating cash consumption nearly tripled. The underwriting cash outflow was Rs47.8 million, and total operating outflow reached Rs85.1 million.
  • The auditor retained qualifications over a Rs330.2 million accrued-interest receivable and the absence of impairment testing on Rs89.4 million advanced against shares in subsidiaries.

Why written premium did not become earned premium

An insurer does not recognize all written premium immediately. Premium is earned across the period in which coverage is provided. When policies are issued late in a reporting period, a larger portion remains in the unearned-premium reserve and is released into revenue later, subject to policy duration, cancellations and endorsements.

That timing explains the apparent contradiction in CSIL’s filing. H1 gross written premium increased by Rs10.3 million, but the closing unearned-premium reserve was Rs23.7 million. Net premium earned therefore fell by Rs16.2 million. In Q2 alone, gross written premium was Rs28.4 million but earned premium was only Rs9.1 million, down 53.7% year on year.

This could create a future revenue tail if the policies remain in force, but it is not automatically positive. The Rs5.8 million premium-deficiency expense says that management’s estimate of remaining claims and expenses was higher than the related unearned premium for affected business. Future reserve releases must therefore be assessed alongside claim emergence, not celebrated as free revenue.

The underwriting economics: expenses, not claims, drove the loss

H1 claims expense rose 19.1% to Rs1.1 million, but it remained only 3.3% of net premium. Net commission expense fell 40.3% to Rs2.7 million. Those two lines were not the main source of deterioration.

Management expense was the decisive burden. It increased by Rs14.2 million to Rs71.6 million and exceeded net premium by Rs36.8 million before claims, commission and the premium-deficiency charge. The underwriting result consequently fell to a Rs46.5 million loss from a Rs10.0 million loss.

Motor generated Rs6.6 million of H1 net premium but recorded a Rs31.2 million underwriting loss after Rs29.8 million of allocated management expenses and a Rs6.5 million premium-deficiency charge. Miscellaneous business contributed Rs23.6 million, or about 67.8% of net premium, yet still lost Rs11.0 million at the underwriting level. The segment data therefore shows a broad fixed-cost problem rather than one bad claim event.

Investment income: a volatile support engine

CSIL’s 2025 profit depended materially on investment performance. That support reversed in H1 2026. Dividend income improved to Rs21.5 million, but realized losses on sales of available-for-sale securities expanded to Rs32.7 million, leaving net investment income at negative Rs11.1 million.

The distinction between realized and unrealized losses matters. The Rs32.7 million disposal loss entered profit or loss and affected the H1 bottom line. Separately, available-for-sale investments recorded a Rs56.9 million unrealized loss in other comprehensive income. That second loss bypassed profit after tax but reduced the investment remeasurement reserve from Rs62.0 million at December to Rs5.0 million at June.

Q2’s positive Rs15.4 million investment income is encouraging but does not erase the H1 volatility. For future results, dividend income is the more recurring component; disposal gains and losses and market-value movements should be treated as variable.

Company result versus group result

The cleanest view of the insurance operation is the unconsolidated result: an Rs50.9 million H1 loss after tax. The consolidated group added Crescent Star Foods, Crescent Star Technologies and Crescent Star Ventures. Group other expenses were Rs14.1 million, compared with Rs4.6 million at the insurer alone, taking consolidated loss after tax to Rs60.4 million.

Subsidiaries therefore added roughly Rs9.5 million of pre-tax drag. This gap is useful when judging business quality: a recovery in insurance underwriting may still be diluted if group ventures continue consuming capital or generating expenses.

Cash flow, capital and balance-sheet quality

The reported Rs6.0 million increase in cash is financing-led, not operating-led. Operations consumed Rs85.1 million and investing consumed Rs7.2 million. Financing produced Rs98.3 million after Rs122.8 million of rights proceeds and Rs24.4 million of loan settlement. Without fresh equity, period-end cash would have been materially weaker.

The rights issue increased ordinary share capital by Rs409.2 million at nominal value, with Rs286.5 million recorded as discount, yielding Rs122.8 million net proceeds. That cash broadly offset the Rs107.9 million total comprehensive loss, so unconsolidated equity still increased 1.1% to Rs1.353 billion. Economically, this is a capital reset, not evidence that the existing business funded itself.

Loans and other receivables were Rs1.017 billion, equal to about 62.5% of unconsolidated assets. Insurance receivables were Rs138.9 million after a Rs71.4 million impairment provision. Equity investments fell to Rs200.2 million from Rs261.8 million. The balance sheet is therefore dominated less by immediately liquid cash and more by receivables, advances and investments whose recoverability and market value matter.

The auditor’s qualification is central, not a footnote

The independent reviewer qualified the H1 unconsolidated statements on two matters. First, CSIL carried Rs330.2 million of accrued interest on an advance originally made against shares in Dost Steels. The reviewer said documentary evidence was not provided, so recoverability could not be established. Management states that charging the interest is legally justified.

Second, the company held Rs89.4 million of advances against shares in subsidiaries without performing the IAS 36 impairment test. The filing therefore contains no provision for any loss that such a test might identify.

Together, these amounts equal roughly one-quarter of unconsolidated equity and about 26% of loans and other receivables. The key issue is not whether they affected H1 cash—they did not—but whether future collection or impairment changes the reported asset base. Readers should keep adjusted liquidity separate from accounting equity until the evidence improves.

Operational and corporate developments

Management says guarantee business has restarted, though Afghan transit guarantees remain suspended because of the border closure. It is issuing guarantees for other Central Asian routes and also prioritizing travel and motor products while monitoring claim ratios. The company identifies bank enlistment and limits as a constraint for smaller insurers. CSIL corporate briefing

The filing also says digital third-party motor policies are being issued following provincial initiatives. This may expand premium writing, but the economics will depend on acquisition cost, claim frequency, pricing and whether enough business is retained to absorb overhead.

A separate strategic path is the court-approved scheme to merge Crescent Star Foods into PICIC Insurance. Management says PICIC would issue about 5.6 billion shares to CSIL and become a subsidiary after completion. This is a proposed structural transformation whose accounting, regulatory and funding effects should be assessed only when shares are issued and closing steps are confirmed.

Sector and peer context

Pakistan’s insurance industry is growing from a low-penetration base. SECP’s 2024 statistics reported total industry gross premiums of Rs677 billion, up 7% year on year, while its June 2026 list confirms the active-insurer universe. SECP Insurance Industry Statistics 2024

That broad growth does not explain CSIL’s loss. Official H1 filings show Atlas Insurance increased net premium 16% to Rs1.913 billion and earned Rs697.0 million of underwriting profit. United Insurance also remained profitable at a much larger operating scale. Product mix and takaful operations differ, so margins are not directly transferable, but the comparison shows that CSIL’s negative result was not an unavoidable sector outcome.

Scale is the critical difference. Atlas’s H1 net premium was about 55 times CSIL’s and its management expense was 37.6% of net premium, compared with CSIL’s 206%. Larger books can spread branches, systems, compliance and staff costs across more earned premium. CSIL’s opportunity is to grow selected lines without weakening underwriting discipline; its risk is that overhead and investment volatility outrun a still-small premium base.

Recurring versus exceptional drivers

  • Recurring weakness until proven otherwise: management expense exceeds earned premium, so core underwriting lacks scale.
  • Potentially recurring improvement: newly written guarantee, motor and travel business may add future earned premium if policies remain in force and pricing covers claims and expenses.
  • Period-specific negative: the Rs32.7 million realized investment disposal loss. It should not be annualized, but investment volatility is a recurring business risk.
  • Exceptional financing: Rs122.8 million of rights proceeds supported cash and equity. It is not revenue or operating cash flow.
  • Ongoing balance-sheet uncertainty: the qualified accrued-interest receivable and untested subsidiary advances remain until resolved, collected or impaired.
  • Strategic optionality rather than current earnings: the PICIC merger and digital motor expansion should be judged through completed regulatory steps, capital deployment and reported results.

What changed versus the historical pattern

CSIL reported annual profit after tax of Rs68.1 million in 2023, Rs87.2 million in 2024 and Rs20.9 million in 2025 on PSX’s company record. H1 2026 broke that profitable pattern because both underwriting and investments were negative at the same time. PSX company record

The quarter split is slightly more constructive than the half-year headline. Q2 loss after tax was Rs11.8 million, versus a derived Rs39.1 million loss in Q1. Q2 investment income recovered and gross written premium accelerated. But Q2 underwriting still lost Rs30.8 million, so the sequential improvement depended on investments and other income rather than a profitable core insurance book.

What to monitor next

  • Earned-premium conversion: whether the Rs23.7 million unearned reserve releases into revenue without adverse cancellations or deficiency charges.
  • Expense ratio: management expense must fall sharply relative to net premium; absolute premium growth alone is insufficient.
  • Guarantee business: issuance volumes outside Afghan transit routes, bank enlistment, limits, fee/premium economics and claim experience.
  • Motor and travel underwriting: premium growth, premium deficiency and segment-level profitability after allocated expenses.
  • Investment quality: realized gains or losses, dividend income and the remaining Rs5.0 million available-for-sale reserve.
  • Operating cash flow: whether the business stops consuming cash after an Rs85.1 million H1 outflow.
  • Qualified balances: documentary support, collection or impairment of the Rs330.2 million accrued-interest receivable and IAS 36 testing of the Rs89.4 million subsidiary advance.
  • PICIC transaction: confirmation of share issuance, ownership, consolidation effects, regulatory approvals and any fresh funding requirement.
  • Group drag: whether subsidiary expenses narrow the gap between unconsolidated and consolidated earnings.

Sources

Explore more research

All articles